Gland Pharma Limited (GLAND.BO)
Gland Pharma Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $2968.80, up 0.06% on the session, giving a market capitalisation of $489.44B. Its beta of 0.48 implies it has historically moved less than the broad market.
Gland Pharma Limited specializes in the production and global distribution of injectable pharmaceutical formulations, with significant markets spanning India, the United States, Europe, Canada, Australia, and New Zealand. The company actively invests in the research and development of active pharmaceutical ingredients (APIs), focusing on the synthesis of complex drug molecules such as low molecular weight heparins (LMWH), corticosteroids, peptides, and cytotoxic agents. Its extensive product portfolio addresses a wide array of therapeutic areas, including anti-malarial, anti-infective, anti-neoplastic, blood-related, cardiovascular, gastrointestinal, gynecological, hormonal, neurological/CNS, ophthalmological/oncological needs, pain and analgesics, respiratory conditions, and nutritional supplements (vitamins, minerals, and nutrients). Complementing its product offerings, Gland Pharma also provides contract development services. Established in 1978 and headquartered in Hyderabad, India, the company operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Gland Pharma Limited is most often compared with the following Healthcare names: